Latest News, Press Releases & Events

Spyryx Biosciences Marks Rare Disease Day With an Update on Clinical Trials for SPX-101

Spyryx Biosciences Marks Rare Disease Day With an Update on Clinical Trials for SPX-101 DURHAM, N.C., February 28, 2017 – Spyryx Biosciences, Inc., a clinical stage biopharmaceutical company developing innovative therapeutics to address severe lung diseases, today announced the details of an upcoming Phase 1b study to evaluate the safety of SPX-101 in patients with […]

Continue Reading

Spyryx Biosciences Announces Successful Completion of Phase 1 Clinical Trial for SPX-101 and Planned Phase 2 Initiation in Cystic Fibrosis During 2017

Spyryx Biosciences Announces Successful Completion of Phase 1 Clinical Trial for SPX-101 and Planned Phase 2 Initiation in Cystic Fibrosis During 2017 Study results indicate SPX-101 was well-tolerated with no dose limiting safety concerns Company has initiated plans for a Phase 2 study to investigate clinical benefit of SPX-101 in treating cystic fibrosis-related lung disease, […]

Continue Reading

Spyryx Biosciences Presents Data at NACFC on SPX-101 Demonstrating Safety, Stability And Efficacy in Animal Models

Spyryx Biosciences Presents Data at NACFC on SPX-101 Demonstrating Efficacy, Safety, and Stability in Animal Models Three posters presented at NACFC 2016 DURHAM, N.C. – November 2, 2016. Three posters presented by Spyryx Biosciences at the North American Cystic Fibrosis Conference provided data that demonstrates the safety, stability and efficacy of SPX-101 in animal models […]

Continue Reading